166 related articles for article (PubMed ID: 23322528)
1. Pharmacokinetics and excretion of 14C-bendamustine in patients with relapsed or refractory malignancy.
Dubbelman AC; Rosing H; Darwish M; D'Andrea D; Bond M; Hellriegel E; Robertson P; Beijnen JH; Schellens JH
Drugs R D; 2013 Mar; 13(1):17-28. PubMed ID: 23322528
[TBL] [Abstract][Full Text] [Related]
2. Metabolite profiling of bendamustine in urine of cancer patients after administration of [14C]bendamustine.
Dubbelman AC; Jansen RS; Rosing H; Darwish M; Hellriegel E; Robertson P; Schellens JH; Beijnen JH
Drug Metab Dispos; 2012 Jul; 40(7):1297-307. PubMed ID: 22492615
[TBL] [Abstract][Full Text] [Related]
3. Development and validation of LC-MS/MS assays for the quantification of bendamustine and its metabolites in human plasma and urine.
Dubbelman AC; Tibben M; Rosing H; Gebretensae A; Nan L; Gorman SH; Robertson P; Schellens JH; Beijnen JH
J Chromatogr B Analyt Technol Biomed Life Sci; 2012 Apr; 893-894():92-100. PubMed ID: 22426286
[TBL] [Abstract][Full Text] [Related]
4. Phase I and pharmacokinetic study of bendamustine hydrochloride in relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma.
Ogura M; Uchida T; Taniwaki M; Ando K; Watanabe T; Kasai M; Matsumoto Y; Shimizu D; Ogawa Y; Ohmachi K; Yokoyama H; Tobinai K;
Cancer Sci; 2010 Sep; 101(9):2054-8. PubMed ID: 20594195
[TBL] [Abstract][Full Text] [Related]
5. Population pharmacokinetics and pharmacokinetics/pharmacodynamics of bendamustine in pediatric patients with relapsed/refractory acute leukemia.
Darwish M; Megason G; Bond M; Hellriegel E; Robertson P; Grasela T; Phillips L
Curr Med Res Opin; 2014 Nov; 30(11):2305-15. PubMed ID: 25105914
[TBL] [Abstract][Full Text] [Related]
6. Simultaneous determination of bendamustine and its active metabolite, gamma-hydroxy-bendamustine in human plasma and urine using HPLC-fluorescence detector: application to a pharmacokinetic study in Chinese cancer patients.
Xie F; Cheng Z; Cheng H; Yu P
J Chromatogr B Analyt Technol Biomed Life Sci; 2014 Jun; 960():98-104. PubMed ID: 24793082
[TBL] [Abstract][Full Text] [Related]
7. A phase I study of bendamustine hydrochloride administered once every 3 weeks in patients with solid tumors.
Rasschaert M; Schrijvers D; Van den Brande J; Dyck J; Bosmans J; Merkle K; Vermorken JB
Anticancer Drugs; 2007 Jun; 18(5):587-95. PubMed ID: 17414628
[TBL] [Abstract][Full Text] [Related]
8. Phase I study of bendamustine with concurrent whole brain radiation therapy in patients with brain metastases from solid tumors.
Pan E; Yu D; Zhao X; Neuger A; Smith P; Chinnaiyan P; Yu HH
J Neurooncol; 2014 Sep; 119(2):413-20. PubMed ID: 24965340
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics, metabolism, and routes of excretion of intravenous irofulven in patients with advanced solid tumors.
Paci A; Rezai K; Deroussent A; De Valeriola D; Re M; Weill S; Cvitkovic E; Kahatt C; Shah A; Waters S; Weems G; Vassal G; Lokiec F
Drug Metab Dispos; 2006 Nov; 34(11):1918-26. PubMed ID: 16896064
[TBL] [Abstract][Full Text] [Related]
10. Bendamustine pharmacokinetic profile and exposure-response relationships in patients with indolent non-Hodgkin's lymphoma.
Owen JS; Melhem M; Passarell JA; D'Andrea D; Darwish M; Kahl B
Cancer Chemother Pharmacol; 2010 Nov; 66(6):1039-49. PubMed ID: 20140617
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of absorption, distribution, metabolism, and excretion of [
Liao M; Watkins S; Nash E; Isaacson J; Etter J; Beltman J; Fan R; Shen L; Mutlib A; Kemeny V; Pápai Z; van Tilburg P; Xiao JJ
Invest New Drugs; 2020 Jun; 38(3):765-775. PubMed ID: 31250355
[TBL] [Abstract][Full Text] [Related]
12. Repeated administration of short infusions of bendamustine: a phase I study in patients with advanced progressive solid tumours.
Schöffski P; Hagedorn T; Grünwald V; Paul H; Merkle K; Kowalski R; Ganser A
J Cancer Res Clin Oncol; 2000 Jan; 126(1):41-7. PubMed ID: 10641748
[TBL] [Abstract][Full Text] [Related]
13. Weekly administration of bendamustine: a phase I study in patients with advanced progressive solid tumours.
Schöffski P; Seeland G; Engel H; Grünwald V; Paul H; Merkle K; Kowalski R; Ganser A
Ann Oncol; 2000 Jun; 11(6):729-34. PubMed ID: 10942063
[TBL] [Abstract][Full Text] [Related]
14. Bendamustine for the treatment of chronic lymphocytic leukemia and rituximab-refractory, indolent B-cell non-Hodgkin lymphoma.
Dennie TW; Kolesar JM
Clin Ther; 2009; 31 Pt 2():2290-311. PubMed ID: 20110042
[TBL] [Abstract][Full Text] [Related]
15. Feasibility and pharmacokinetic study of bendamustine hydrochloride in combination with rituximab in relapsed or refractory aggressive B cell non-Hodgkin's lymphoma.
Ogura M; Ando K; Taniwaki M; Watanabe T; Uchida T; Ohmachi K; Matsumoto Y; Tobinai K;
Cancer Sci; 2011 Sep; 102(9):1687-92. PubMed ID: 21624007
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic and pharmacodynamic profile of bendamustine and its metabolites.
Darwish M; Bond M; Hellriegel E; Robertson P; Chovan JP
Cancer Chemother Pharmacol; 2015 Jun; 75(6):1143-54. PubMed ID: 25829094
[TBL] [Abstract][Full Text] [Related]
17. Open-label bendamustine monotherapy for pediatric patients with relapsed or refractory acute leukemia: efficacy and tolerability.
Fraser C; Brown P; Megason G; Ahn HS; Cho B; Kirov I; Frankel L; Aplenc R; Bensen-Kennedy D; Munteanu M; Weaver J; Harker-Murray P
J Pediatr Hematol Oncol; 2014 May; 36(4):e212-8. PubMed ID: 24072240
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics, metabolism, and excretion of (14)C-labeled belinostat in patients with recurrent or progressive malignancies.
Calvo E; Reddy G; Boni V; García-Cañamaque L; Song T; Tjornelund J; Choi MR; Allen LF
Invest New Drugs; 2016 Apr; 34(2):193-201. PubMed ID: 26769244
[TBL] [Abstract][Full Text] [Related]
19. A phase I study of bendamustine hydrochloride administered day 1+2 every 3 weeks in patients with solid tumours.
Rasschaert M; Schrijvers D; Van den Brande J; Dyck J; Bosmans J; Merkle K; Vermorken JB
Br J Cancer; 2007 Jun; 96(11):1692-8. PubMed ID: 17486132
[TBL] [Abstract][Full Text] [Related]
20. Absorption, metabolism, and excretion of 14C-temozolomide following oral administration to patients with advanced cancer.
Baker SD; Wirth M; Statkevich P; Reidenberg P; Alton K; Sartorius SE; Dugan M; Cutler D; Batra V; Grochow LB; Donehower RC; Rowinsky EK
Clin Cancer Res; 1999 Feb; 5(2):309-17. PubMed ID: 10037179
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
